A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti-PD-1 Resistance through Effects on the Gut Microbiota
Meriem Messaoudene,Reilly Pidgeon,Corentin Richard,Mayra Ponce,Khoudia Diop,Myriam Benlaifaoui,Alexis Nolin-Lapalme,Florent Cauchois,Julie Malo,Wiam Belkaid,Stephane Isnard,Yves Fradet,Lharbi Dridi,Dominique Velin,Paul Oster,Didier Raoult,François Ghiringhelli,Romain Boidot,Sandy Chevrier,David T Kysela,Yves V Brun,Emilia Liana Falcone,Geneviève Pilon,Florian Plaza Oñate,Oscar Gitton-Quent,Emmanuelle Le Chatelier,Sylvere Durand,Guido Kroemer,Arielle Elkrief,André Marette,Bastien Castagner,Bertrand Routy
DOI: https://doi.org/10.1158/2159-8290.CD-21-0808
2022-04-01
Abstract:Several approaches to manipulate the gut microbiome for improving the activity of cancer immune-checkpoint inhibitors (ICI) are currently under evaluation. Here, we show that oral supplementation with the polyphenol-rich berry camu-camu (CC; Myrciaria dubia) in mice shifted gut microbial composition, which translated into antitumor activity and a stronger anti-PD-1 response. We identified castalagin, an ellagitannin, as the active compound in CC. Oral administration of castalagin enriched for bacteria associated with efficient immunotherapeutic responses (Ruminococcaceae and Alistipes) and improved the CD8+/FOXP3+CD4+ ratio within the tumor microenvironment. Moreover, castalagin induced metabolic changes, resulting in an increase in taurine-conjugated bile acids. Oral supplementation of castalagin following fecal microbiota transplantation from ICI-refractory patients into mice supported anti-PD-1 activity. Finally, we found that castalagin binds to Ruminococcus bromii and promoted an anticancer response. Altogether, our results identify castalagin as a polyphenol that acts as a prebiotic to circumvent anti-PD-1 resistance. Significance: The polyphenol castalagin isolated from a berry has an antitumor effect through direct interactions with commensal bacteria, thus reprogramming the tumor microenvironment. In addition, in preclinical ICI-resistant models, castalagin reestablishes the efficacy of anti-PD-1. Together, these results provide a strong biological rationale to test castalagin as part of a clinical trial. This article is highlighted in the In This Issue feature, p. 873.